• UCB Pharma
September 21, 2018

April 5 – UCB SA:

* UCB STRENGTHENS RESEARCH CAPABILITIES WITH ACQUISITION OF ELEMENT GENOMICS, A DUKE UNIVERSITY BIOTECH SPIN-OFF

* ‍TOTAL COST OF TRANSACTION WILL AMOUNT TO UP TO USD 30 MILLION​

* ‍ELEMENT GENOMICS’ TEAM WILL CONTINUE TO BE BASED IN DOWNTOWN DURHAM, WILL WORK CLOSELY WITH UCB’S RESEARCH TEAMS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)